NeuroGen

NeuroGen was co-founded by CBC Group, a leading investment institution in Asia's healthcare sector, and Mubadala, a globally renowned investment firm. Originating from the mature business segment of UCB, a global biopharmaceutical company, in China, NeuroGen completed its restructuring through a strategic acquisition in 2024.Adhering to the core mission of "Innovation for a Better Life," the company focuses on neuroscience as its strategic core while expanding into key areas such as pain management, pediatrics, and allergy. We are committed to becoming a platform-based biopharmaceutical enterprise with sustainable growth, providing superior clinical treatment solutions and more accessible innovative therapies to safeguard patients' health and well-being.